233 related articles for article (PubMed ID: 8996351)
41. [Metastatic prostate cancer associated with low levels of prostate-specific antigen].
Diaz S; Salirrosas M
Rev Peru Med Exp Salud Publica; 2012; 29(4):541-4. PubMed ID: 23338642
[TBL] [Abstract][Full Text] [Related]
42. Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literature.
Safa AA; Reese DM; Carter DM; Phillipson J; Smith R; Dougherty S
Am J Clin Oncol; 1998 Aug; 21(4):323-6. PubMed ID: 9708626
[TBL] [Abstract][Full Text] [Related]
43. Can serum prostate-specific antigen replace bone scintigraphy in the follow-up of metastatic prostatic cancer?
Sissons GR; Clements R; Peeling WB; Penney MD
Br J Radiol; 1992 Oct; 65(778):861-4. PubMed ID: 1384917
[TBL] [Abstract][Full Text] [Related]
44. Dramatic PSA Increase With Tumor Shrinkage After Initiating Degarelix in Advanced Prostate Cancer.
Ammannagari N; Javvaji C; Danchaivijitr P; George S
Clin Genitourin Cancer; 2016 Feb; 14(1):e123-5. PubMed ID: 26508365
[No Abstract] [Full Text] [Related]
45. Is prostate-specific antigen a reliable marker of bone metastasisin patients with newly diagnosed cancer of the prostate?
Gontero P; Muir GH
Eur Urol; 1998 Dec; 34(6):518-9. PubMed ID: 9831795
[No Abstract] [Full Text] [Related]
46. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.
Takeuchi S; Arai K; Saitoh H; Yoshida K; Miura M
J Urol; 1996 Nov; 156(5):1691-5. PubMed ID: 8863572
[TBL] [Abstract][Full Text] [Related]
47. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
[TBL] [Abstract][Full Text] [Related]
48. [Bone scintigraphy findings in patients with recently diagnosed adenocarcinoma of the prostate: relationship with prostate specific antigen levels].
Ortega A; Alonso JC; Suárez M; Domínguez P; Almoguera I; Bittini A; Gómez A; Martínez L; Herranz F; Pérez-Vázquez JM
Rev Esp Med Nucl; 2000 Oct; 19(6):409-15. PubMed ID: 11060270
[TBL] [Abstract][Full Text] [Related]
49. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
50. Investigation of the safety and accuracy of intraoperative gamma probe directed biopsy of bone scan detected rib abnormalities in prostatic adenocarcinoma.
Thurman SA; Robinson LA; Ahmad N; Pow-Sang JM; Lockhart JL; Seigne J
J Urol; 2003 Apr; 169(4):1341-4. PubMed ID: 12629356
[TBL] [Abstract][Full Text] [Related]
51. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
Yoshida K; Sumi S; Arai K; Koga F; Umeda H; Hosoya Y; Honda M; Yano M; Moriguchi H; Kitahara S
Cancer; 1997 Nov; 80(9):1760-7. PubMed ID: 9351545
[TBL] [Abstract][Full Text] [Related]
52. [Bone scintigraphy in prostatic cancer. Correlation with clinical and laboratory features and with survival].
Lobo G; Ladrón de Guevara D; Salgado G; Donoso G; Bagus F
Rev Med Chil; 1999 Feb; 127(2):181-8. PubMed ID: 10436698
[TBL] [Abstract][Full Text] [Related]
53. Prognostic factors in metastatic prostate cancer.
Yigitbasi O; Ozturk U; Goktug HN; Gucuk A; Bakirtas H
Urol Oncol; 2011; 29(2):162-5. PubMed ID: 19450995
[TBL] [Abstract][Full Text] [Related]
54. [Diagnostic value of urinary N-telopeptide of type I collagen in prostate cancer: comparison with bone scintigraphy].
Fukumitsu N; Uchiyama M; Mori Y; Yanada S; Hatano T; Igarashi H; Nakada J
Kaku Igaku; 1999 May; 36(4):333-9. PubMed ID: 10390956
[TBL] [Abstract][Full Text] [Related]
55. [Clinical evaluation on serum osteocalcin in advanced prostate cancer patients].
Abe H; Nakagami YJ; Ito H; Ikeda K; Oka F; Niwa N
Hinyokika Kiyo; 1991 Aug; 37(8):877-80. PubMed ID: 1720275
[TBL] [Abstract][Full Text] [Related]
56. Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: implications for paracrine growth.
Doherty A; Smith G; Banks L; Christmas T; Epstein RJ
J Pathol; 1999 Jul; 188(3):278-81. PubMed ID: 10419596
[TBL] [Abstract][Full Text] [Related]
57. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy.
Cher ML; Bianco FJ; Lam JS; Davis LP; Grignon DJ; Sakr WA; Banerjee M; Pontes JE; Wood DP
J Urol; 1998 Oct; 160(4):1387-91. PubMed ID: 9751361
[TBL] [Abstract][Full Text] [Related]
58. [Usefulness of bone gammagraphy versus tumor markers (PSA/PAP) in monitoring cancer of the prostate].
Morote J; de Torres JA
Actas Urol Esp; 1990; 14(4):268-70. PubMed ID: 1702258
[TBL] [Abstract][Full Text] [Related]
59. [When should bone scanning be carried out in prostatic cancer?].
Pertusa Peña C; Albisu Tristán A; Llarena Ibarguren R
Actas Urol Esp; 1994 May; 18 Suppl():387-96. PubMed ID: 8073924
[TBL] [Abstract][Full Text] [Related]
60. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
